systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075082X.2020.2.200235systhiper-629Research ArticleОБЗОРREVIEWЛАГ: за рамками идиопатической формы патологииPAH: beyond the idiopathic form of diseaseМартынюкТ. В.MartynyukT. A.info@eco-vector.comШмальцА. А.ShmaltsA. A.info@eco-vector.comКлименкоА. А.KlimenkoA. A.info@eco-vector.comИнститут клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РоссииРоссияInstitute of Clinical Cardiology. A.L. Myasnikov Federal State Budgetary Institution "National Medical Research Center of Cardiology" of the Ministry of Health of RussiaRussian FederationФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава РоссииРоссияBakoulev Scientific Center for Cardiovascular SurgeryRussian FederationФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияNesterov Department of Faculty Therapy Pirogov Russian National Research Medical UniversityRussian Federation2020231220221728490Copyright © Мартынюк Т.В., Шмальц А.А., Клименко А.А., 20222022Мартынюк Т.В., Шмальц А.А., Клименко А.А.Martynyuk T.A., Shmalts A.A., Klimenko A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/629

VIII Евразийский конгресс кардиологов. Обзор симпозиумов. ЛАГ: за рамками идиопатической формы патологии. Системные гипертензии.

VIII Eurasian Congress of Cardiology. Overview of symposiums. PAH: beyond the idiopathic form of disease. Systemic Hypertension.

ReferencesChannick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary artery hypertension: A randomized placebo-controlled study. Lancet 2001; 358: 1119-23Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary artery hypertension: A randomized placebo-controlled study. Lancet 2001; 358: 1119-23Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903Barst RJ, Ivy D, van Giersbergen PL et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Therapeutics 2003; 73: 372-82Barst RJ, Ivy D, van Giersbergen PL et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Therapeutics 2003; 73: 372-82Galiè N, Beghetti M, Gatzoulis MA et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54Galiè N, Beghetti M, Gatzoulis MA et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54Galie N, Rubin LJ, Jansa P et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized, controlled trial. Lancet 2008; 371: 2093-100Galie N, Rubin LJ, Jansa P et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized, controlled trial. Lancet 2008; 371: 2093-100Sitbon O, Gressin V, Speich R et al. Bosentan in pulmonary arterial hypertension associated with HIV infection. Am J Respir Crit Care Med 2004; 170: 1212-7Sitbon O, Gressin V, Speich R et al. Bosentan in pulmonary arterial hypertension associated with HIV infection. Am J Respir Crit Care Med 2004; 170: 1212-7Hughes RJ, Jais X, Bonderman D et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 year. Eur Respir J 2006; 28: 138-43Hughes RJ, Jais X, Bonderman D et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 year. Eur Respir J 2006; 28: 138-43Bonderman D, Nowotny R, Skoro-Sajer N et al. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest 2005; 128: 2599-603Bonderman D, Nowotny R, Skoro-Sajer N et al. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest 2005; 128: 2599-603Provencher S, Sitbon O, Humbert M et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-95Provencher S, Sitbon O, Humbert M et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-95Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92: 926-32Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92: 926-32Rosenzweig EB, Ivy DD, Widlitz A et al. Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. JACC 2005; 46 (4): 697-704Rosenzweig EB, Ivy DD, Widlitz A et al. Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. JACC 2005; 46 (4): 697-704Jais X, Ghofrani A, Hoeper MM et al. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a randomized, placebo-controlled trial. Am J Resp Crit Care Med 2007; 173: A896Jais X, Ghofrani A, Hoeper MM et al. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a randomized, placebo-controlled trial. Am J Resp Crit Care Med 2007; 173: A896Guillevin L, Gabrielli A, Peter H et al. Long-term effects of bosentan on quality of life (QoL), survival, safety and tolerability in pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD). Ann Rheum Dis 2006; 65 (Suppl. 2): 392Guillevin L, Gabrielli A, Peter H et al. Long-term effects of bosentan on quality of life (QoL), survival, safety and tolerability in pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD). Ann Rheum Dis 2006; 65 (Suppl. 2): 392Keogh AM, McNeil KD, Wlodarczyk J et al. Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan. J Heart Lung Transplantation 2007; 26: 181-7Keogh AM, McNeil KD, Wlodarczyk J et al. Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan. J Heart Lung Transplantation 2007; 26: 181-7Galie N, Seeger W, Naeije R et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S-88SGalie N, Seeger W, Naeije R et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S-88SАрхипова О.А., Грацианская С.Е., Мартынюк Т.В. Оценка эффективности и безопасности первого российского генерического бозентана у пациентов с легочной артериальной гипертензией. Системные гипертензии. 2018; 15 (4): 53-8Архипова О.А., Грацианская С.Е., Мартынюк Т.В. Оценка эффективности и безопасности первого российского генерического бозентана у пациентов с легочной артериальной гипертензией. Системные гипертензии. 2018; 15 (4): 53-8McLaughlin V, Channick RN, Ghofrani H-A et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405-13McLaughlin V, Channick RN, Ghofrani H-A et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405-13Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-4Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-4Simonneau G, Montani D, Celermajer DS et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (1). DOI: 10.1183/13993003.01913-2018Simonneau G, Montani D, Celermajer DS et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (1). DOI: 10.1183/13993003.01913-2018Galie N, Beghettie M, Gatzoulis MA et al. Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. Circulation 2006; 114: 48-54Galie N, Beghettie M, Gatzoulis MA et al. Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. Circulation 2006; 114: 48-54Galié N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67-119. DOI: 10.1093/eurheartj/ehv317Galié N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67-119. DOI: 10.1093/eurheartj/ehv317Hansmann G, Koestenberger M, Alastalo TP et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 2019; 38 (9): 879-901. DOI: 10.1016/j.healun.2019.06.022Hansmann G, Koestenberger M, Alastalo TP et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 2019; 38 (9): 879-901. DOI: 10.1016/j.healun.2019.06.022Galie N et al. Treatment of Patients With Mildly Symptomatic Pulmonary Arterial Hypertension With Bosentan (EARLY Study): A Double-Blind, Randomised Controlled Trial. Lancet 2008; 371: 2093-100Galie N et al. Treatment of Patients With Mildly Symptomatic Pulmonary Arterial Hypertension With Bosentan (EARLY Study): A Double-Blind, Randomised Controlled Trial. Lancet 2008; 371: 2093-100McLaughlin V et al. Bosentan Added to Sildenafil Therapy in Patients With Pulmonary Arterial Hypertension. Eur Respir J 2015; 46: 405-13McLaughlin V et al. Bosentan Added to Sildenafil Therapy in Patients With Pulmonary Arterial Hypertension. Eur Respir J 2015; 46: 405-13Torbicki A et al, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005; 353 (20): 2148-57. DOI: 10.1056/NEJMoa050010Torbicki A et al, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005; 353 (20): 2148-57. DOI: 10.1056/NEJMoa050010Simonneau G et al. Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients With Pulmonary Arterial Hypertension: A Randomized Trial. Ann Intern Med 2008; 149: 521-30Simonneau G et al. Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients With Pulmonary Arterial Hypertension: A Randomized Trial. Ann Intern Med 2008; 149: 521-30Pulido T et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809-18Pulido T et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809-18Ghofrani HA, Galiè N, Grimminger F et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369 (4): 330-40. DOI: 10.1056/NEJMoa1209655Ghofrani HA, Galiè N, Grimminger F et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369 (4): 330-40. DOI: 10.1056/NEJMoa1209655Beghetti M, Channick RN, Chin KM et al. Selexipag Treatment for Pulmonary Arterial Hypertension Associated With Congenital Heart Disease After Defect Correction: Insights From the Randomised Controlled GRIPHON Study. Eur J Heart Fail 2019; 21 (3): 352-9. DOI: 10.1002/ejhf.1375Beghetti M, Channick RN, Chin KM et al. Selexipag Treatment for Pulmonary Arterial Hypertension Associated With Congenital Heart Disease After Defect Correction: Insights From the Randomised Controlled GRIPHON Study. Eur J Heart Fail 2019; 21 (3): 352-9. DOI: 10.1002/ejhf.1375Rosenkranz S, Ghofrani HA, Beghetti M et al. Riociguat for Pulmonary Arterial Hypertension Associated With Congenital Heart Disease. Heart 2015; 101 (22): 1792-9. DOI: 10.1136/heartjnl-2015-307832Rosenkranz S, Ghofrani HA, Beghetti M et al. Riociguat for Pulmonary Arterial Hypertension Associated With Congenital Heart Disease. Heart 2015; 101 (22): 1792-9. DOI: 10.1136/heartjnl-2015-307832Beghetti M, Channick RN, Chin KM et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail 2018. DOI: 10.1002/ejhf.1375Beghetti M, Channick RN, Chin KM et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail 2018. DOI: 10.1002/ejhf.1375Galie N et al. Evaluation of macitentan in patients with Eisenmenger syndrome: Results from the randomised controlled MAESTRO study. Eur Heart J 2017; 38 (Suppl 1): P5462. https://academic.oup.com/eurheartj/article/38/suppl_1/ehx493.P5462/4086822Galie N et al. Evaluation of macitentan in patients with Eisenmenger syndrome: Results from the randomised controlled MAESTRO study. Eur Heart J 2017; 38 (Suppl 1): P5462. https://academic.oup.com/eurheartj/article/38/suppl_1/ehx493.P5462/4086822Singh TP, Rohit M, Grover A et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151 (4): 851.e1-5. DOI: 10.1016/j.ahj.2005.09.006Singh TP, Rohit M, Grover A et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151 (4): 851.e1-5. DOI: 10.1016/j.ahj.2005.09.006Sun YJ, Yang T, Zeng WJ et al. Impact of sildenafil on survival of patients with Eisenmenger syndrome. J Clin Pharmacol 2013; 53 (6): 611-8Sun YJ, Yang T, Zeng WJ et al. Impact of sildenafil on survival of patients with Eisenmenger syndrome. J Clin Pharmacol 2013; 53 (6): 611-8Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger’s syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. Cardiol Young 2011; 21 (6): 631-8. DOI: 10.1017/s1047951111000497Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger’s syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. Cardiol Young 2011; 21 (6): 631-8. DOI: 10.1017/s1047951111000497Zhang Z-N, Jiang X, Zhang R et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 2011; 97 (22): 1876-81. DOI: 10.1136/heartjnl-2011-300344Zhang Z-N, Jiang X, Zhang R et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 2011; 97 (22): 1876-81. DOI: 10.1136/heartjnl-2011-300344Zuckerman WA, Leaderer D, Rowan CA et al. Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease. Am J Cardiol 2011; 107 (9): 1381-5. DOI: 10.1016/j.amjcard.2010.12.051Zuckerman WA, Leaderer D, Rowan CA et al. Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease. Am J Cardiol 2011; 107 (9): 1381-5. DOI: 10.1016/j.amjcard.2010.12.051Min Ku Chon, Kyoung Im Cho, Kwang Soo Cha et al. Effects of Long-Term Iloprost Treatment on Right Ventricular Function in Patients With Eisenmenger Syndrome. J Cardiol 2017; 69 (5): 741-6. DOI: 10.1016/j.jjcc.2016.07.002Min Ku Chon, Kyoung Im Cho, Kwang Soo Cha et al. Effects of Long-Term Iloprost Treatment on Right Ventricular Function in Patients With Eisenmenger Syndrome. J Cardiol 2017; 69 (5): 741-6. DOI: 10.1016/j.jjcc.2016.07.002Dimopoulos K, Inuzuka R, Goletto S et al. Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy for Pulmonary Arterial Hypertension. Circulation 2010; 121 (1): 20-5. DOI: 10.1161/CIRCULATIONAHA.109.883876Dimopoulos K, Inuzuka R, Goletto S et al. Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy for Pulmonary Arterial Hypertension. Circulation 2010; 121 (1): 20-5. DOI: 10.1161/CIRCULATIONAHA.109.883876Li Q, Kuang HY, Wu YH et al. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis. Medicine 2019; 98 (20): e15632. DOI: 10.1097/md.0000000000015632Li Q, Kuang HY, Wu YH et al. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis. Medicine 2019; 98 (20): e15632. DOI: 10.1097/md.0000000000015632Kuang HY, Wu YH, Yi QJ et al. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97 (10): e0075. DOI: 10.1097/MD.0000000000010075Kuang HY, Wu YH, Yi QJ et al. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97 (10): e0075. DOI: 10.1097/MD.0000000000010075Varela DL, Teleb M, El-Mallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review. Open Heart 2018; 5 (1): e000744. DOI: 10.1136/openhrt-2017-000744Varela DL, Teleb M, El-Mallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review. Open Heart 2018; 5 (1): e000744. DOI: 10.1136/openhrt-2017-000744Kozlik-Feldman R et al. Pulmonary Hypertension in Children With Congenital Heart Disease (PAH-CHD, PPHVD-CHD). Expert Consensus Statement on the Diagnosis and Treatment of Paediatric Pulmonary Hypertension. The European Paediatric Pulmonary Vascular Disease Network, Endorsed by ISHLT and DGPK. Heart 2016; 102: ii42-ii48Kozlik-Feldman R et al. Pulmonary Hypertension in Children With Congenital Heart Disease (PAH-CHD, PPHVD-CHD). Expert Consensus Statement on the Diagnosis and Treatment of Paediatric Pulmonary Hypertension. The European Paediatric Pulmonary Vascular Disease Network, Endorsed by ISHLT and DGPK. Heart 2016; 102: ii42-ii48Abman SH et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015; 132 (21)Abman SH et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015; 132 (21)Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Легочная артериальная гипертензия, ассоциированная с врожденными пороками сердца у взрослых. Методическое пособие. М.: НЦССХ им. А.Н.Бакулева, 2016; с. 833-50Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Легочная артериальная гипертензия, ассоциированная с врожденными пороками сердца у взрослых. Методическое пособие. М.: НЦССХ им. А.Н.Бакулева, 2016; с. 833-50Горбачевский С.В., Шмальц А.А., Плотникова Л.Р. Легочная гипертензия у детей с врожденными пороками сердца. М., 2018Горбачевский С.В., Шмальц А.А., Плотникова Л.Р. Легочная гипертензия у детей с врожденными пороками сердца. М., 2018Hansmann G, Koestenberger M, Alastalo T-P et al. 2019 Updated Consensus Statement on the Diagnosis and Treatment of Pediatric Pulmonary Hypertension. The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplantation 2019. DOI: 10.1016/j.healunHansmann G, Koestenberger M, Alastalo T-P et al. 2019 Updated Consensus Statement on the Diagnosis and Treatment of Pediatric Pulmonary Hypertension. The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplantation 2019. DOI: 10.1016/j.healunLim ZS, Vettukattill JJ, Salmon AP et al. Sildenafil therapy in complex pulmonary atresia with pulmonary arterial hypertension. Int J Cardiol 2008; 129 (3): 339-43. DOI: 10.1016/j.ijcard.2007.08.016Lim ZS, Vettukattill JJ, Salmon AP et al. Sildenafil therapy in complex pulmonary atresia with pulmonary arterial hypertension. Int J Cardiol 2008; 129 (3): 339-43. DOI: 10.1016/j.ijcard.2007.08.016Hosein RB, Clarke AJ, McGuirk SP et al. Factors influencing early and late outcome following the Fontan procedure in the current era. The ‘Two Commandments’? Eur J Cardiothorac 2007; 31 (3): 344-53Hosein RB, Clarke AJ, McGuirk SP et al. Factors influencing early and late outcome following the Fontan procedure in the current era. The ‘Two Commandments’? Eur J Cardiothorac 2007; 31 (3): 344-53Bowater SE, Weaver RA, Thorne SA, Clift PF. The safety and effects of bosentan in patients with a Fontan circulation. Congenital Heart Dis 2012; 7 (3): 243-9Bowater SE, Weaver RA, Thorne SA, Clift PF. The safety and effects of bosentan in patients with a Fontan circulation. Congenital Heart Dis 2012; 7 (3): 243-9Shang XK, Li YP, Liu M et al. Efficacy of Endothelin Receptor Antagonist Bosentan on the Long-Term Prognosis in Patients After Fontan Operation. Zhonghua Xin Xue Guan Bing Za Zhi 2013; 41 (12): 1025-8Shang XK, Li YP, Liu M et al. Efficacy of Endothelin Receptor Antagonist Bosentan on the Long-Term Prognosis in Patients After Fontan Operation. Zhonghua Xin Xue Guan Bing Za Zhi 2013; 41 (12): 1025-8Schuuring MJ, Vis JC, van Dijk AP et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail 2013; 15 (6): 690-8Schuuring MJ, Vis JC, van Dijk AP et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail 2013; 15 (6): 690-8Hebert A, Mikkelsen UR, Thilen U et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation 2014; 130 (23): 2021-30Hebert A, Mikkelsen UR, Thilen U et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation 2014; 130 (23): 2021-30Derk G, Houser L, Miner P et al. Efficacy of Endothelin Blockade in Adults with Fontan Physiology. Congenital Heart Dis 2015; 10 (1): E11-E16Derk G, Houser L, Miner P et al. Efficacy of Endothelin Blockade in Adults with Fontan Physiology. Congenital Heart Dis 2015; 10 (1): E11-E16Shang XK, Lu R, Zhang X et al. Efficacy of Bosentan in patients after Fontan procedures: a double-blind, randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci 2016; 36 (4): 534-40. DOI: 10.1007/s11596-016-1621-8Shang XK, Lu R, Zhang X et al. Efficacy of Bosentan in patients after Fontan procedures: a double-blind, randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci 2016; 36 (4): 534-40. DOI: 10.1007/s11596-016-1621-8Giardini A, Balducci A, Specchia S et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29 (13): 1681-7. https://doi.org/10.1093/eurheartj/ehn215Giardini A, Balducci A, Specchia S et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29 (13): 1681-7. https://doi.org/10.1093/eurheartj/ehn215Reinhardt Z, Uzun O, Bhole V et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010; 20 (5): 522-5. DOI: 10.1017/S1047951110000648Reinhardt Z, Uzun O, Bhole V et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010; 20 (5): 522-5. DOI: 10.1017/S1047951110000648Ciliberti P, Giardini A. Impact of oral chronic administration of sildenafil in children and young adults after the Fontan operation. Future Cardiol 2011; 7 (5): 609-12. DOI: 10.2217/fca.11.52Ciliberti P, Giardini A. Impact of oral chronic administration of sildenafil in children and young adults after the Fontan operation. Future Cardiol 2011; 7 (5): 609-12. DOI: 10.2217/fca.11.52Van De Bruaene A, La Gerche A, Claessen G et al. Sildenafil Improves Exercise Hemodynamics in Fontan Patients. Circulation: Cardiovascular Imaging 2014; 7 (2): 265-73. DOI: 10.1161/circimaging.113.001243Van De Bruaene A, La Gerche A, Claessen G et al. Sildenafil Improves Exercise Hemodynamics in Fontan Patients. Circulation: Cardiovascular Imaging 2014; 7 (2): 265-73. DOI: 10.1161/circimaging.113.001243Mori H, Park IS, Yamagishi H et al. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. Int J Cardiol 2016; 221: 122-7. https://doi.org/10.1016/j.ijcard.2016.06.322Mori H, Park IS, Yamagishi H et al. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. Int J Cardiol 2016; 221: 122-7. https://doi.org/10.1016/j.ijcard.2016.06.322Collins JLG, Law MA, Borasino S et al. Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation. Pediatr Cardiol 2017; 38 (8): 1703-8. DOI: 10.1007/s00246-017-1716-4Collins JLG, Law MA, Borasino S et al. Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation. Pediatr Cardiol 2017; 38 (8): 1703-8. DOI: 10.1007/s00246-017-1716-4Agnoletti G, Gala S, Ferroni F et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thoracic Cardiovasc Surg 2017; 153 (6): 1468-75. DOI: 10.1016/j.jtcvs.2017.01.051Agnoletti G, Gala S, Ferroni F et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thoracic Cardiovasc Surg 2017; 153 (6): 1468-75. DOI: 10.1016/j.jtcvs.2017.01.051Cedars AM, Saef J, Peterson LR et al. Effect of Ambrisentan on Exercise Capacity in Adult Patients After the Fontan Procedure. Am J Cardiol 2016; 117 (9): 1524-32. DOI: 10.1016/j.amjcard.2016.02.024Cedars AM, Saef J, Peterson LR et al. Effect of Ambrisentan on Exercise Capacity in Adult Patients After the Fontan Procedure. Am J Cardiol 2016; 117 (9): 1524-32. DOI: 10.1016/j.amjcard.2016.02.024Rhodes J, Ubeda-Tikkanen A, Clair M et al. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol 2013; 168 (3): 2435-40. DOI: 10.1016/j.ijcard.2013.03.014Rhodes J, Ubeda-Tikkanen A, Clair M et al. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol 2013; 168 (3): 2435-40. DOI: 10.1016/j.ijcard.2013.03.014Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J 2014; 35 (11): 691-700. https://doi.org/10.1093/eurheartj/eht437Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J 2014; 35 (11): 691-700. https://doi.org/10.1093/eurheartj/eht437Yamamura K, Nagata H, Ikeda K et al. Efficacy of bosentan therapy for segmental pulmonary artery hypertension due to major aortopulmonary collateral arteries in children. Int J Cardiol 2016; 161 (1): e1-e3Yamamura K, Nagata H, Ikeda K et al. Efficacy of bosentan therapy for segmental pulmonary artery hypertension due to major aortopulmonary collateral arteries in children. Int J Cardiol 2016; 161 (1): e1-e3Onat A, Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 2012; 18 (11): 1465-77. DOI: 10.2174/138161212799504740Onat A, Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 2012; 18 (11): 1465-77. DOI: 10.2174/138161212799504740Попкова Т.В. и др. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008Попкова Т.В. и др. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008Hoeper MM, Apitz C, Grünig E et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S: 37-45. DOI: 10.1016/j.ijcard.2018.08.082Hoeper MM, Apitz C, Grünig E et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S: 37-45. DOI: 10.1016/j.ijcard.2018.08.082Рекомендации Ассоциации ревматологов России по лечению ССД. 2016Рекомендации Ассоциации ревматологов России по лечению ССД. 2016Рекомендации Европейской противоревматической лиги по лечению ССДРекомендации Европейской противоревматической лиги по лечению ССДChazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Ter Arkh 2019; 91 (1): 24-31. DOI: 10.26442/00403660.2019.01.000024Chazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Ter Arkh 2019; 91 (1): 24-31. DOI: 10.26442/00403660.2019.01.000024Hamaguchi Y, Sumida T, Kawaguchi Y et al. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. J Dermatol 2017; 44 (1): 13-7. DOI: 10.1111/1346-8138.13497Hamaguchi Y, Sumida T, Kawaguchi Y et al. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. J Dermatol 2017; 44 (1): 13-7. DOI: 10.1111/1346-8138.13497Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70 (1): 32-8. DOI: 10.1136/ard.2010.130658Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70 (1): 32-8. DOI: 10.1136/ard.2010.130658

The authors declare that there are no conflicts of interest present.